What Biosphere does

Biosphere (legal entity Arcology Inc.) is a privately held Oakland, California-based industrial biotechnology company founded in 2022 by Brian Heligman (CEO) and Arye Lipman (COO). The company designs and manufactures commercial-scale bioreactors that replace legacy steam-in-place sterilization with a proprietary UV sterilize-in-place protocol. This architectural shift enables 10x cheaper reactor materials, only 33% of the valves and pipes of steam-sterilized systems, and roughly 6x faster sterilization cycles, with the company reporting complete sterilization of spore-filled reactors 100 times out of 100. The platform spans pilot, 2,000L demonstration, 20,000L reference-plant, and full-scale commercial reactor configurations, paired with tightly integrated proprietary controls software that manages the upstream fermentation workflow from media prep through DSP sizing.

Biosphere commercializes the platform through three revenue streams: (1) long-term contract manufacturing using its own reactor capacity for 0.2–20 m³ batches, (2) sale and installation of commercial-scale Biosphere reactors at third-party biomanufacturing facilities to expand customer in-house capacity, and (3) government/defense contracts delivered through Other Transaction Authority (OTA) agreements. The commercial go-to-market is direct enterprise sales targeting bioproduct companies with $10–100M ARR across therapeutics, enzymes, proteins, bioplastics, fertilizers, and jet fuel applications. Pricing is not publicly disclosed and is arranged through a "Get in Touch" contact flow. As of May 2026, the company's largest disclosed contract is a $9 million, 42-month U.S. Army DEVCOM Soldier Center OTA awarded via the Office of the Undersecretary of War Manufacturing Science and Technology Program to develop a portable, field-deployable biomanufacturing system that synthesizes protein rations from air, water, and energy for forward-deployed warfighters.

Biosphere emerged from stealth in January 2025 with an $8.8 million seed financing led by Lowercarbon Capital and VXI Capital, with participation from Also Capital, B37 Ventures, Caffeinated Capital, Founders Fund, and GS Futures. It is described as a small, founder-led team of engineers and scientists (1–10 employees) with expertise spanning commercial-scale fermentation, robotic greenhouses, thin-film semiconductors, and bioinformatics. The company's stated next major milestone is a commercial-scale manufacturing facility with 100–1,000 m³ of reactor capacity.

Name

Biosphere

Legal name

Arcology Inc.

Website

https://biosphere.io

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Biosphere (Arcology Inc.) is an Oakland-based industrial biotechnology company that designs and manufactures UV-sterilized bioreactors replacing legacy steam sterilization, selling reactors and contract manufacturing services to $10–100M ARR bioproduct companies across therapeutics, fuels, and bioplastics.

Ownership category

akta.pro rank

Product category

Industrial Bioreactors / Biomanufacturing Equipment

NAICS

Food Product Machinery Manufacturing (333241), Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252)

SIC

Industrial & Commercial Fans & Blowers & Air Purifing Equip (3564)

akta.pro primary industry

Bioprocess Facility, Cleanroom & Utility Systems (HVAC, WFI, CIP/SIP, containment) (HLAAAJAJ)

Keywords

• Industrial bioreactors
• Biomanufacturing equipment
• Fermentation systems
• UV sterilization technology
• Contract biomanufacturing

Headquarters

HQ city

Oakland

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel

Revenue model

1. Long-term Contract Manufacturing: Biosphere offers contract manufacturing using its own reactor capacity at its manufacturing sites for batches of 0.2 to 20 cubic meters, available to committed technology partners.
2. Reactor Sales and Installation: Biosphere sells and installs commercial-scale reactors into third-party biomanufacturing facilities, enabling customers to expand their own in-house capacity.
3. Government/Defense Contracts: Biosphere secures milestone-based government agreements such as the $9M Other Transaction Authority (OTA) agreement from the U.S. Army DEVCOM SC, consisting of a baseline effort and three subsequent options.

Pricing tiers

Go-to-market motion3 records

Core offering

Biosphere designs and manufactures commercial-scale UV-sterilized bioreactor systems for industrial fermentation, replacing legacy steam-in-place sterilization with a proprietary UV approach. It sells and installs these reactors at third-party biomanufacturing sites and provides long-term contract manufacturing services for batches of 0.2 to 20 cubic meters. Its government-grade application is a portable, field-deployable biomanufacturing system that produces protein rations from air, water, and energy for warfighters.

Product overview

Biosphere offers a single integrated biomanufacturing platform built around its proprietary UV-Sterilized Bioreactor System, augmented by tightly integrated proprietary Controls Software to deliver a complete upstream solution. The platform is commercialized through three go-to-market offerings: (1) Long-Term Contract Manufacturing Service (running 0.2–20 m³ batches at Biosphere sites), (2) In-House Capacity Expansion (installing commercial-scale Biosphere reactors in third-party biomanufacturing facilities), and (3) the recently announced Portable Biomanufacturing Nutrition Production System (Warfighter Ration System) developed under a U.S. Army contract to produce on-demand protein rations for forward-deployed troops. Target applications span therapeutics, enzymes, proteins, bioplastics, fertilizers, and jet fuel.

Differentiator

Problem solved

Functional benefit

Products and services

• UV-Sterilized Bioreactor System Biosphere's flagship hardware platform — a modern bioreactor that replaces 1950s-era steam-in-place sterilization with a UV sterilize-in-place protocol. Delivers aseptic environments using 10x cheaper materials, only 33% of the valves/pipes of legacy systems, and 6x faster sterilization. For commercial-scale fermentation of therapeutics, enzymes, proteins, bioplastics, fertilizers, and jet fuel.
• Long-Term Contract Manufacturing Service Contract manufacturing service using Biosphere's existing reactor capacity at its manufacturing sites for batches of 0.2 to 20 cubic meters. Targets $10–100M ARR bioproduct companies that need to scale production without building their own facilities.
• In-House Capacity Expansion (Reactor Installation) Service offering commercial-scale Biosphere reactors for installation in third-party biomanufacturing facilities, enabling bioproduct companies to bring the UV-sterilized platform in-house and expand their own production capacity.
• Portable Biomanufacturing Nutrition Production System (Warfighter Ration System) Field-deployable, portable biomanufacturing system built on Biosphere's UV-sterilized bioreactor platform that synthesizes ready-to-eat protein rations from air, water, and energy. Designed to produce 2,800 calories per person per day for up to 18 warfighters (scalable to 250 personnel) in contested, remote, and logistically constrained environments. Developed under a 42-month, up-to-$9 million U.S. Army OTA contract.
• Integrated Controls Software Proprietary controls software tightly integrated with Biosphere's UV bioreactor hardware, delivering optimal system-level performance for the complete upstream fermentation workflow — impacting media prep, fermenter performance, and downstream processing (DSP) sizing.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Culture Biosciences: Offers bioreactor-based contract manufacturing services for bioproduct companies, directly overlapping with Biosphere's contract manufacturing GTM. Targets similar early-stage bioproduct customers seeking fermentation capacity without in-house infrastructure.
• LanzaTech: Operates commercial-scale gas fermentation bioreactors producing fuels and chemicals from industrial emissions. Comparable as a fermentation-led industrial biomanufacturer with capital-intensive reactor infrastructure at commercial scale.
• Solugen: Industrial biomanufacturer using fermentation to produce specialty chemicals at scale. Competes for the same bioproduct customer base targeting lower-cost, sustainable manufacturing of materials Biosphere enables through its UV-sterilized reactors.
• PBS Biotech: Manufacturer of single-use bioreactors for cell and gene therapy bioprocessing. Directly comparable as a bioreactor hardware vendor pursuing cost and operational improvements versus traditional stainless-steel steam-sterilized systems.
• ABEC: Long-established custom bioreactor manufacturer serving vaccine, therapeutic, and industrial biotech. A direct incumbent competing for commercial-scale reactor sales against Biosphere's UV-sterilized offering.

Broad incumbents

• Ginkgo Bioworks: Large-scale synthetic biology platform with biomanufacturing capabilities, including its recent acquisition of bioprocess tooling assets (Zymergen). Competes broadly in the same 'programmable biology' thesis as Biosphere, though Ginkgo's focus is on cell engineering rather than reactor hardware.
• Sartorius: Global bioprocessing equipment leader offering stainless-steel and single-use bioreactors and process software. The dominant incumbent whose installed base of steam-sterilized systems Biosphere seeks to disrupt.
• Cytiva (Danaher): Provides bioreactors, fermentation equipment, and bioprocess solutions to pharma and biotech. Major incumbent whose legacy Xcellerex and stainless-steel reactor lines are the most direct competitors to Biosphere's value proposition.
• Amyris: Industrial synthetic biology company that scaled fermentation-based biomanufacturing of specialty ingredients before its bankruptcy and restructuring. A cautionary comparable demonstrating both the promise and execution risk of scaling fermentation-led industrial bioproducts.

Emerging players

• Bota Bio: Engineering biology company developing and scaling biomanufacturing processes for specialty chemicals and ingredients. Comparable as an emerging bioproduct developer that represents a potential customer for Biosphere's contract manufacturing or reactor sales.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biosphereio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosphere